Entegris, Inc. Cell & Gene Tech Expo August 2025: Cell Therapy

There are many challenges to scalability and continuous processing for allogeneic therapies that will need to be addressed to reduce production costs and ensure stable supply. One such consideration for both the production of viral vectors and for large scale cell therapies is the high weight % of solids in concentrated and process intensified bioreactors. As the titers increase, it is critical to reduce hold-up and utilize smaller surface area devices, achieving high flux and throughput to keep processing times short and eliminate loss.

Another area that requires optimization is freezing and storage of those cells once they are separated. How do you balance the need to keep individual containers small to reduce the risk of loss, with the need to freeze larger volumes of cells in a consistent and controlled manner? This presentation will provide insights into how to accomplish these things in a closed system process using existing off-the-shelf solutions.